Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease

Diabetes

Volumn 64, Issue 6, 2015, Pages 1933-1940

  Willette, Auriel A ^a,c   Modanlo, Nina ^b   Kapogiannis, Dimitrios ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c IOWA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; BRAIN SIZE; CLINICAL DEMENTIA RATING; COGNITION; COHORT ANALYSIS; DRUG METABOLISM; EXECUTIVE FUNCTION; FEMALE; GLOBAL CEREBRUM; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; HYPERMETABOLISM; INSULIN RESISTANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDIAL TEMPORAL LOBE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTCENTRAL GYRUS; PRIORITY JOURNAL; BRAIN; METABOLISM; PATHOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY;

EID: 84964697985     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1507     Document Type: Article

References (47)

1. Irie F, Fitzpatrick AL, Lopez OL, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: The Cardiovascular Health Study Cognition Study. Arch Neurol 2008;65:89-93.
2. Yaffe K, Falvey C, Hamilton N, et al. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol 2012;69: 1170-1175.
3. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002;90:3G-10G.
4. Schrijvers EM, Witteman JC, Sijbrands EJ, Hofman A, Koudstaal PJ, Breteler MM. Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study. Neurology 2010;75:1982-1987.
5. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: The road map to cardiovascular diseases. Diabetes Metab Res Rev 2006;22: 423-436.
6. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Arch Neurol 2009;66:300-305.
7. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004;3:169-178.
8. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012;122:1316-1338.
9. Willette AA, Bendlin BB, Colman RJ, et al. Calorie restriction reduces the influence of glucoregulatory dysfunction on regional brain volume in aged rhesus monkeys. Diabetes 2012;61:1036-1042.
10. Rasgon NL, Kenna HA, Wroolie TE, et al. Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease. Neurobiol Aging 2011;32: 1942-1948.
11. García-Casares N, Berthier ML, Jorge RE, et al. Structural and functional brain changes in middle- Aged type 2 diabetic patients: A cross-sectional study. J Alzheimers Dis 2014;40:375-386.
12. Kapogiannis D, Boxer A, Schwartz JB, et al. Dysfunctionally phosphorylated IRS-1 in neural-derived blood exosomes of preclinical Alzheimer's disease. FASEB J. 23 October 2014 [Epub ahead of print].
13. Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ. Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol 2007;42:129-138.
14. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol 2012;69:29-38.
15. Chen K, Ayutyanont N, Langbaum JB, et al.; Alzheimer's Disease Neuroimaging Initiative. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 2011;56:52-60.
16. Shokouhi S, Claassen D, Kang H, et al. Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET. J Nucl Med 2013;54:1564-1569.
17. Anthony K, Reed LJ, Dunn JT, et al. Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: The cerebral basis for impaired control of food intake in metabolic syndrome? Diabetes 2006;55:2986-2992.
18. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 2011;68:51-57.
19. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
21. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410.
22. Willette AA, Xu G, Johnson SC, et al. Insulin resistance, brain atrophy, and cognitive performance in late middle- Aged adults. Diabetes Care 2013;36:443-449.
23. Morris JK, Vidoni ED, Honea RA, Burns JM; Alzheimer's Disease Neuroimaging Initiative. Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol Aging 2014;35:585-589.
24. Gibbons LE, Carle AC, Mackin RS, et al.; Alzheimer's Disease Neuroimaging Initiative. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 2012;6:517-527.
25. Crane PK, Carle A, Gibbons LE, et al.; Alzheimer's Disease Neuroimaging Initiative. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 2012;6: 502-516.
26. Samuraki M, Matsunari I, Chen WP, et al. Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease. Eur J Nucl Med Mol Imaging 2007;34:1658-1669.
27. Ou Y, Sotiras A, Paragios N, Davatzikos C. DRAMMS: deformable registration via attribute matching and mutual-saliency weighting. Med Image Anal 2011;15:622-639.
28. Ou Y, Akbari H, Bilello M, Da X, Davatzikos C. Comparative evaluation of registration algorithms in different brain databases with varying difficulty: Results and insights. IEEE Trans Med Imaging 2014;33:2039-2065.
29. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010;6:221-229.
30. Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: A reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 1995;19:541-547.
31. Dukart J, Mueller K, Villringer A, et al.; Alzheimer's Disease Neuroimaging Initiative. Relationship between imaging biomarkers, age, progression and symptom severity in Alzheimer's disease. Neuroimage Clin 2013;3:84-94.
32. Ewers M, Brendel M, Rizk-Jackson A, et al.; Alzheimer's Disease Neuroimaging Initiative (ADNI). Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. Neuroimage Clin 2014;4:45-52.
33. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement 2012;8:S1-S68.
34. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
35. Aiken L, West S. Multiple Regression: Testing and Interpreting Interactions. Newbury Park, CA, Sage, 1991.
36. Kawasaki K, Ishii K, Saito Y, Oda K, Kimura Y, Ishiwata K. Influence of mild hyperglycemia on cerebral FDG distribution patterns calculated by statistical parametric mapping. Ann Nucl Med 2008;22:191-200.
37. Mormino EC, Smiljic A, Hayenga AO, et al. Relationships between b- Amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex 2011;21:2399-2407.
38. Miller SL, Celone K, DePeau K, et al. Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. Proc Natl Acad Sci U S A 2008;105:2181-2186.
39. Sperling RA, Dickerson BC, Pihlajamaki M, et al. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med 2010;12: 27-43.
40. Haier RJ, Alkire MT, White NS, et al. Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia. Neurology 2003;61:1673-1679.
41. Scheef L, Spottke A, Daerr M, et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology 2012;79:1332-1339.
42. Cohen AD, Price JC, Weissfeld LA, et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: An example of brain reserve. J Neurosci 2009;29:14470-144778.
43. Burns JM, Donnelly JE, Anderson HS, et al. Peripheral insulin and brain structure in early Alzheimer disease. Neurology 2007;69:1094-1104.
44. Burns JM, Honea RA, Vidoni ED, Hutfles LJ, Brooks WM, Swerdlow RH. Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging. Biochim Biophys Acta 2012;1822:333-339.
45. Kleinridders A, Ferris HA, Cai W, Kahn CR. Insulin action in brain regulates systemic metabolism and brain function. Diabetes 2014;63:2232-2243.
46. De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 2009;106:1971-1976.
47. Chiu SL, Chen CM, Cline HT. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 2008;58: 708-719.